ClinicalTrials.gg
CompletedNCT02122471CICUpdated May 28, 2019Results posted

12-Week Study of Plecanatide for CIC (The National CIC3 Study)

A Phase 3 interventional study of Plecanatide and Placebo in Chronic Idiopathic Constipation, sponsored by Bausch Health Americas, Inc.. Completed at 167 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2019-05-28.

Sponsored by Bausch Health Americas, Inc. (part of Bausch Health Companies Inc.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
1,410
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 12 studies testing plecanatide in Constipation — none open to participants now, 1 under way, none of them phase 3. plecanatide · Constipation.

Enrollment
2nd of 12
1,410 · median 800
Started
2014
with 1 other
Phase 3
6 of 12
none open now
Registered
6th of 12
by date
Lead sponsor
11 of 12
Bausch Health Americas, Inc.

Among the 12 studies testing plecanatide in Constipation, this one is the 2nd largest by enrollment, is one of 2 that started in 2014, is one of 6 in phase 3, and was the 6th registered.

Constipation

1,047 studies on the registry are indexed under Constipation; 161 are open to participants now.

Browse Constipation studies →

Open to participants now

None of the 12 studies testing plecanatide in Constipation is open now. The open studies under Constipation, anywhere →

Where they have run

About plecanatide

plecanatide: first FDA approval 2017 (TRULANCE). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 99 Constipation studies recruiting now, 32 (32%) set no upper age limit and 52 (53%) stop at 75 or younger; 17 take children under 18; 28 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 12 studies testing plecanatide in Constipation as a file.
02

Study summary

The purpose of this study is to confirm that the investigational medication, plecanatide, is safe and effective in treating chronic idiopathic constipation.

Read the detailed description

This is a national, randomized, 12-week, double-blind, placebo-controlled, study in approximately 1350 adult male and female patients with CIC comparing 2 doses of plecanatide to placebo. The study will be conducted at approximately 180 clinical study sites in the United States. The primary objective of the study is to evaluate the efficacy and safety of 3.0 and 6.0 mg of plecanatide administered once daily (QD) for 12 weeks in a population of patients with CIC. The study population will include only patients without other causes of constipation or other chronic conditions that could interfere with study assessments. Patients may not take laxatives (with the exception of the study-provided rescue medication, bisacodyl 5mg tablets), or a number of prohibited drugs that are known to cause constipation or diarrhea, during study participation.

There are 6 scheduled study visits, including the screening and follow-up visits. The planned duration of participation in this study will be 112 days and up to 155 days, with washout and all visit windows considered.

03

Conditions studied

  • Chronic Idiopathic Constipation

Browse trials for

Keywords

  • CIC
  • Constipation
  • Chronic Constipation
  • Synergy
  • Plecanatide
04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged 18-80, inclusive
  • Meets modified Rome III criteria for functional chronic idiopathic constipation for at least 3 months with symptom onset for at least 6 months
  • Completed a colonoscopy in accordance with American Gastroenterological Association (AGA) colon cancer screening guidelines (5 years), with no findings
  • Willing to maintain a stable diet during the study

Exclusion criteria

Exclusion Criteria:

  • Loose stool (mushy) or watery (Bristol score 6 or 7) stool in the absence of any laxative or prohibited medicine for > 25% of Bowel Movements (BMs) during the 3 months prior to screening visit OR during the 14 day pre-treatment assessment
  • Active peptic ulcer disease, diabetes or hypertension not adequately treated or not stable
  • History of cathartic colon, laxative, enema abuse, or ischemic colitis
  • Fecal impaction within 3 months of screening
  • Patient has had /has any: diseases or conditions associated with constipation (GI or CNS), structural abnormality of the GI tract or gastric bypass surgery, pelvic floor dysfunction, pseudo-obstruction, active infectious gastritis, diverticulitis, anal fissures or any disease or condition that can affect GI motility or defecation or can be associated with abdominal pain
  • Unexplained and "alarm symptoms" including lower GI bleeding, iron-deficiency anemia, weight loss or systemic signs of infection or colitis
  • Major surgery, stroke or myocardial infarction (MI) within 60 days of screening
  • Participated in a previous plecanatide clinical trial
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
1,410 participants (actual)

Study arms

  • Experimental
    Plecanatide 3.0 mg

    Plecanatide tablets 3.0 mg QD for 12 weeks

    Drug: Plecanatide

  • Placebo comparator
    Placebo

    Matching placebo tablets QD for 12 weeks

    Drug: Placebo

  • Experimental
    Plecanatide 6.0 mg

    Plecanatide tablets 6.0 mg QD for 12 weeks

    Drug: Plecanatide

Interventions

06

What researchers measure

Primary outcomes

  1. Number of Durable Overall CSBM Responders, Mean Replacement Approach

    The primary efficacy endpoint was measured by the number of durable overall CSBM responders over the 12-week Treatment Period. A durable overall CSBM responder was defined as a weekly CSBM responder for at least 9 of the 12 treatment weeks, including at least 3 of the last 4 weeks. A CSBM weekly responder was defined as a patient who has ≥ 3 Complete Spontaneous Bowel Movements (CSBMs) per week and an increase from baseline of ≥1 CSBM for that week. A CSBM was a bowel movement that occurred in the absence of laxative use within 24 hours and was associated with the feeling of complete evacuation.

    Time frame: 12-Week Treatment Period

Secondary outcomes

  1. Change From Baseline in CSBMs (CSBMs/Week) Over the 12-week Treatment Period , Mean Replacement Approach

    The change from baseline in the number of Complete Spontaneous Bowel Movements (CSBMs) over the 12-week Treatment Period was analyzed. Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. A CSBM was a bowel movement that occurred in the absence of laxative use within 24 hours and was associated with the feeling of complete evacuation.

    Time frame: Baseline and 12 weeks

  2. Change From Baseline in SBMs (SBMs/Week) Over the 12-week Treatment Period, Mean Replacement Approach

    The change from baseline in the number of Spontaneous Bowel Movement (SBM) over the 12-week Treatment Period was analyzed. Baseline was the mean number of SBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly SBM totals were derived from the daily diary entries reported during the Treatment Period.

    Time frame: Baseline and 12 weeks

  3. Change From Baseline in Average Weekly SBM Stool Consistency Over the 12-week Treatment Period, Mean Replacement Approach

    The change from baseline in the stool consistency score (i.e. BSFS) over the 12-week Treatment Period was analyzed. Baseline was the mean BSFS score recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly mean BSFS score per patient was derived from the BSFS entries reported during the Treatment Period in the Daily Symptom Diary. The stool consistency of each bowel movement (BM) was assessed by patients using the 7-point Bristol Stool Form Scale \[BSFS\] from 1 to 7. 1. = separate hard lumps like nuts (difficult to pass) 2. = sausage shaped but lumpy 3. = like a sausage but with cracks on its surface 4. = like a sausage or snake, smooth and soft 5. = soft blobs with clear-cut edges (passed easily) 6. = fluffy pieces with ragged edges, a mushy stool 7. = watery, no solid pieces (entirely liquid)

    Time frame: Baseline and 12 weeks

  4. Change From Baseline in Average Weekly Straining Score Over the 12-week Treatment Period, Mean Replacement Approach

    The change from baseline in the straining score over the 12-week Treatment Period was analyzed. Baseline was the mean of non-missing straining scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly average straining score was derived from the straining scores reported during the Treatment Period in the Daily Symptom Diary. The severity of straining during bowel movements was assessed on a 5-point Likert scale where 0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.

    Time frame: Baseline and 12 weeks

07

Results

Posted Mar 14, 2019

Participant flow

Participant flow — Overall Study
MilestonePlaceboPlecanatide 3 mgPlecanatide 6 mg
Started445443449
Completed406392405
Not completed395144

Outcome measures

PrimaryNumber of Durable Overall CSBM Responders, Mean Replacement Approach

The primary efficacy endpoint was measured by the number of durable overall CSBM responders over the 12-week Treatment Period. A durable overall CSBM responder was defined as a weekly CSBM responder for at least 9 of the 12 treatment weeks, including at least 3 of the last 4 weeks. A CSBM weekly responder was defined as a patient who has ≥ 3 Complete Spontaneous Bowel Movements (CSBMs) per week and an increase from baseline of ≥1 CSBM for that week. A CSBM was a bowel movement that occurred in the absence of laxative use within 24 hours and was associated with the feeling of complete evacuation.

Time frame:
12-Week Treatment Period
Reported as:
Count of participants · Participants
Number of Durable Overall CSBM Responders, Mean Replacement Approach
ParticipantsPlaceboPlecanatide 3 mgPlecanatide 6 mg
Number of Durable Overall CSBM Responders, Mean Replacement Approach578888
SecondaryChange From Baseline in CSBMs (CSBMs/Week) Over the 12-week Treatment Period , Mean Replacement Approach

The change from baseline in the number of Complete Spontaneous Bowel Movements (CSBMs) over the 12-week Treatment Period was analyzed. Baseline was the mean number of CSBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. A CSBM was a bowel movement that occurred in the absence of laxative use within 24 hours and was associated with the feeling of complete evacuation.

Time frame:
Baseline and 12 weeks
Reported as:
Least squares mean · CSBMs per week
Change From Baseline in CSBMs (CSBMs/Week) Over the 12-week Treatment Period , Mean Replacement Approach
CSBMs per weekPlaceboPlecanatide 3 mgPlecanatide 6 mg
Baseline1.41 ± 0.1382.34 ± 0.1392.19 ± 0.138
12 weeks1.69 ± 0.1592.66 ± 0.1622.50 ± 0.159
SecondaryChange From Baseline in SBMs (SBMs/Week) Over the 12-week Treatment Period, Mean Replacement Approach

The change from baseline in the number of Spontaneous Bowel Movement (SBM) over the 12-week Treatment Period was analyzed. Baseline was the mean number of SBMs recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly SBM totals were derived from the daily diary entries reported during the Treatment Period.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · SBMs per week
Change From Baseline in SBMs (SBMs/Week) Over the 12-week Treatment Period, Mean Replacement Approach
SBMs per weekPlaceboPlecanatide 3 mgPlecanatide 6 mg
Baseline1.55 ± 1.5911.79 ± 2.0841.63 ± 1.673
12 weeks1.81 ± 2.8793.25 ± 3.9383.10 ± 4.164
SecondaryChange From Baseline in Average Weekly SBM Stool Consistency Over the 12-week Treatment Period, Mean Replacement Approach

The change from baseline in the stool consistency score (i.e. BSFS) over the 12-week Treatment Period was analyzed. Baseline was the mean BSFS score recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly mean BSFS score per patient was derived from the BSFS entries reported during the Treatment Period in the Daily Symptom Diary. The stool consistency of each bowel movement (BM) was assessed by patients using the 7-point Bristol Stool Form Scale \[BSFS\] from 1 to 7. 1. = separate hard lumps like nuts (difficult to pass) 2. = sausage shaped but lumpy 3. = like a sausage but with cracks on its surface 4. = like a sausage or snake, smooth and soft 5. = soft blobs with clear-cut edges (passed easily) 6. = fluffy pieces with ragged edges, a mushy stool 7. = watery, no solid pieces (entirely liquid)

Time frame:
Baseline and 12 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Average Weekly SBM Stool Consistency Over the 12-week Treatment Period, Mean Replacement Approach
score on a scalePlaceboPlecanatide 3 mgPlecanatide 6 mg
Baseline2.35 ± 1.0902.16 ± 1.0362.27 ± 1.113
12 weeks1.02 ± 1.3461.71 ± 1.4751.59 ± 1.497
SecondaryChange From Baseline in Average Weekly Straining Score Over the 12-week Treatment Period, Mean Replacement Approach

The change from baseline in the straining score over the 12-week Treatment Period was analyzed. Baseline was the mean of non-missing straining scores recorded during the 2-week baseline diary assessment period prior to the first dose of study drug. The weekly average straining score was derived from the straining scores reported during the Treatment Period in the Daily Symptom Diary. The severity of straining during bowel movements was assessed on a 5-point Likert scale where 0 = none, 1 = mild, 2 = moderate, 3 = severe, and 4 = very severe.

Time frame:
Baseline and 12 weeks
Reported as:
Mean · score on a scale
Change From Baseline in Average Weekly Straining Score Over the 12-week Treatment Period, Mean Replacement Approach
score on a scalePlaceboPlecanatide 3 mgPlecanatide 6 mg
Baseline2.42 ± 0.8552.46 ± 0.8592.47 ± 0.888
12 weeks-0.79 ± 1.132-1.09 ± 1.092-1.04 ± 1.084

Adverse events

Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—8/466 (1.7%)15/466 (3.2%)
Plecanatide 3 mg—8/467 (1.7%)25/467 (5.4%)
Plecanatide 6 mg—4/469 (0.9%)31/469 (6.6%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventPlaceboPlecanatide 3 mgPlecanatide 6 mg
Non-cardiac chest painGeneral disorders1/4660/4670/469
Femoral neck fractureInjury, poisoning and procedural complications1/4660/4670/469
Alanine aminotransferase increasedInvestigations1/4660/4670/469
Intervertebral disc protrusionMusculoskeletal and connective tissue disorders1/4660/4670/469
Abortion spontaneousPregnancy, puerperium and perinatal conditions1/4660/4670/469
PregnancyPregnancy, puerperium and perinatal conditions1/4661/4671/469
NephrolithiasisRenal and urinary disorders1/4660/4670/469
Arterial occlusive diseaseVascular disorders1/4660/4670/469
Cardiac failure congestiveCardiac disorders0/4661/4670/469
Vertigo positionalEar and labyrinth disorders0/4661/4670/469
Most frequent other events
Most frequent other events
EventPlaceboPlecanatide 3 mgPlecanatide 6 mg
DiarrhoeaGastrointestinal disorders6/46615/46721/469
HeadacheNervous system disorders9/46610/46710/469

Baseline characteristics

Age, Continuous
Age, Continuous(years)PlaceboPlecanatide 3 mgPlecanatide 6 mgTotal
Mean44.6 ± 14.5945.5 ± 14.3845.3 ± 14.4745.1 ± 14.47
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboPlecanatide 3 mgPlecanatide 6 mgTotal
Female3503453531048
Male959896289
08

Study locations

167 sites
  • Synergy Research Site
    Anniston, Alabama 36207, United States
  • Synergy Research Site
    Huntsville, Alabama 35801, United States
  • Synergy Research Site
    Chandler, Arizona 85224, United States
  • Synergy Research Site
    Goodyear, Arizona 85395, United States
  • Synergy Research Site
    Tucson, Arizona 85704, United States
  • Synergy Research Site
    Tucson, Arizona 85710, United States
  • Synergy Research Site
    Tucson, Arizona 85712, United States
  • Synergy Research Site
    Tucson, Arizona 85715, United States
  • Synergy Research Site
    Tucson, Arizona 85745, United States
  • Synergy Research Site
    Anaheim, California 92801, United States
  • Synergy Research Site
    Artesia, California 90701, United States
  • Synergy Research Site
    Carmichael, California 95608, United States
  • Synergy Research Site
    Corona, California 92879, United States
  • Synergy Research Site
    Encino, California 91436, United States
  • Synergy Research Site
    Garden Grove, California 92843, United States
  • Synergy Research Site
    Garden Grove, California 92844, United States
  • Synergy Research Site
    Glendale, California 91204, United States
  • Synergy Research Site
    La Mirada, California 90638, United States
  • Synergy Research Site
    Laguna Hills, California 92653, United States
  • Synergy Research Site
    Los Angeles, California 90017, United States
  • Synergy Research Site
    Los Angeles, California 90036, United States
  • Synergy Research Site
    Newport Beach, California 92663, United States
  • Synergy Research Site
    Oceanside, California 92056, United States
  • Synergy Research Site
    Orange, California 92868, United States
  • Synergy Research Site
    Sacramento, California 95821, United States
  • Synergy Research Site
    Sacramento, California 95831, United States
  • Synergy Research Site
    San Bernardino, California 92408, United States
  • Synergy Research Site
    San Diego, California 92103, United States
  • Synergy Research Site
    Upland, California 91786, United States
  • Synergy Research Site
    Ventura, California 93003, United States
  • Synergy Research Site
    Denver, Colorado 80209, United States
  • Synergy Research Site
    Littleton, Colorado 80128, United States
  • Synergy Research Site
    Stamford, Connecticut 06905, United States
  • Synergy Research Site
    Aventura, Florida 33180, United States
  • Synergy Research Site
    Boynton Beach, Florida 33472, United States
  • Synergy Research Site
    Bradenton, Florida 34208, United States
  • Synergy Research Site
    Brandon, Florida 33511, United States
  • Synergy Research Site
    Brooksville, Florida 34601, United States
  • Synergy Research Site
    Clearwater, Florida 33756, United States
  • Synergy Research Site
    DeLand, Florida 32720, United States
  • Synergy Research Site
    Fort Lauderdale, Florida 33312, United States
  • Synergy Research Site
    Gainesville, Florida 32607, United States
  • Synergy Research Site
    Hialeah, Florida 33012, United States
  • Synergy Research Site
    Hialeah, Florida 33013, United States
  • Synergy Research Site
    Hialeah, Florida 33016, United States
  • Synergy Research Site
    Hialeah, Florida 33106, United States
  • Synergy Research Site
    Hollywood, Florida 33024, United States
  • Synergy Research Site
    Homestead, Florida 33030, United States
  • Synergy Research Site
    Jacksonville, Florida 32256, United States
  • Synergy Research Site
    Jacksonville, Florida 32277, United States
  • Synergy Research Site
    Miami Lakes, Florida 33016, United States
  • Synergy Research Site
    Miami Springs, Florida 33166, United States
  • Synergy Research Site
    Miami, Florida 33014, United States
  • Synergy Research Site
    Miami, Florida 33015, United States
  • Synergy Research Site
    Miami, Florida 33032, United States
  • Synergy Research Site
    Miami, Florida 33122, United States
  • Synergy Research Site
    Miami, Florida 33125, United States
  • Synergy Research Site
    Miami, Florida 33126, United States
  • Synergy Research Site
    Miami, Florida 33142, United States
  • Synergy Research Site
    Miami, Florida 33144, United States
  • Synergy Research Site
    Miami, Florida 33155, United States
  • Synergy Research Site
    Miami, Florida 33157, United States
  • Synergy Research Site
    Miami, Florida 33165, United States
  • Synergy Research Site
    Miami, Florida 33173, United States
  • Synergy Research Site
    Miami, Florida 33175, United States
  • Synergy Research Site
    Miami, Florida 33176, United States
  • Synergy Research Site
    Miami, Florida 33185, United States
  • Synergy Research Site
    New Port Richey, Florida 34653, United States
  • Synergy Research Site
    North Miami Beach, Florida 33162, United States
  • Synergy Research Site
    Orlando, Florida 32806, United States
  • Synergy Research Site
    Orlando, Florida 32807, United States
  • Synergy Research Site
    Ormond Beach, Florida 32174, United States
  • Synergy Research Site
    Pembroke Pines, Florida 33026, United States
  • Synergy Research Site
    Pembroke Pines, Florida 33028, United States
  • Synergy Research Site
    Plant City, Florida 33563, United States
  • Synergy Research Site
    Plantation, Florida 33324, United States
  • Synergy Research Site
    Saint Cloud, Florida 34769, United States
  • Synergy Research Site
    Saint Petersburg, Florida 33709, United States
  • Synergy Research Site
    Sarasota, Florida 34242, United States
  • Synergy Research Site
    Seminole, Florida 33777, United States
  • Synergy Research Site
    Tamarac, Florida 33319, United States
  • Synergy Research Site
    Tampa, Florida 33607, United States
  • Synergy Research Site
    Tampa, Florida 33614, United States
  • Synergy Research Site
    West Palm Beach, Florida 33409, United States
  • Synergy Research Site
    Atlanta, Georgia 30342, United States
  • Synergy Research Site
    Savannah, Georgia 31406, United States
  • Synergy Research Site
    Snellville, Georgia 30078, United States
  • Synergy Research Site
    Blackfoot, Idaho 83221, United States
  • Synergy Research Site
    Boise, Idaho 83709, United States
  • Synergy Research Site
    Chicago, Illinois 60602, United States
  • Synergy Research Site
    Oak Lawn, Illinois 60453, United States
  • Synergy Research Site
    Schaumburg, Illinois 60194, United States
  • Synergy Research Site
    Evansville, Indiana 47714, United States
  • Synergy Research Site
    Madisonville, Kentucky 42431, United States
  • Synergy Research Site
    Owensboro, Kentucky 42303, United States
  • Synergy Research Site
    Monroe, Louisiana 71201, United States
  • Synergy Research Site
    Shreveport, Louisiana 71105, United States
  • Synergy Research Site
    Columbia, Maryland 21045, United States
  • Synergy Research Site
    Watertown, Massachusetts 02472, United States
  • Synergy Research Site
    Buckley, Michigan 49620, United States

Showing the first 100 of 167 sites. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Moshiree B, Schoenfeld P, Franklin H, Rezaie A. The Effect of Acid Suppression Therapy on the Safety and Efficacy of Plecanatide: Analysis of Randomized Phase III Trials. Clin Ther. 2022 Jan;44(1):98-110.e1. doi: 10.1016/j.clinthera.2021.11.009. Epub 2022 Jan 25. PubMed 35086735 ↗
  • Menees SB, Franklin H, Chey WD. Evaluation of Plecanatide for the Treatment of Chronic Idiopathic Constipation and Irritable Bowel Syndrome With Constipation in Patients 65 Years or Older. Clin Ther. 2020 Jul;42(7):1406-1414.e4. doi: 10.1016/j.clinthera.2020.05.012. Epub 2020 Jul 10. PubMed 32660770 ↗
  • DeMicco M, Barrow L, Hickey B, Shailubhai K, Griffin P. Randomized clinical trial: efficacy and safety of plecanatide in the treatment of chronic idiopathic constipation. Therap Adv Gastroenterol. 2017 Nov;10(11):837-851. doi: 10.1177/1756283X17734697. Epub 2017 Oct 25. PubMed 29147135 ↗
10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2014, a primary completion of May 2015 and a completion of Jul 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Mar 2019, 3 years 10 months after primary completion. A results delay was requested in Apr 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 22, 2014
First posted
Apr 24, 2014
Start
Apr 2014
Primary completionActual
May 2015
CompletionActual
Jul 2015
Results delay requested
Apr 26, 2016
Results first posted
Mar 14, 2019
Last update
May 28, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02122471
Responsible party
Sponsor
First posted
Apr 24, 2014
Start date
Apr 2014
Primary completion
May 2015
Completion
Jul 2015
Results posted
Mar 14, 2019
Last update
May 28, 2019

Study contacts

Mary Beth Layton
study director · Synergy Pharmaceuticals Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Plecanatide

Start the discussion